Full year trading update

AI SummaryClose X

Novacyt S.A. announced an unaudited full-year trading update for 2025, with revenues of approximately £20.0 million, meeting market expectations and showing sequential half-year revenue growth. The Clinical segment generated £13.8 million in sales, driven by a new APAC customer and over 10% growth in NIPT technologies, while the Instrumentation segment saw over 25% growth to £2.5 million, primarily due to the LightBench® Discover instrument. The RUO segment declined by approximately 10% to £3.7 million. The APAC region achieved the highest year-on-year growth of about 10%, with sales of £5.5 million. The Group maintained sequential half-year growth, with revenues rising from £9.6 million in H2 2024 to £10.2 million in H2 2025. EBITDA losses are expected to meet or improve upon market expectations due to cost management. The cash position at year-end was £19.2 million, with the Group remaining debt-free.

Disclaimer*

UK 100

Latest directors dealings